uniQure (NASDAQ:QURE) Insider Walid Abi-Saab Sells 1,434 Shares

uniQure N.V. (NASDAQ:QURE) insider Walid Abi-Saab sold 1,434 shares of the company’s stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $46.86, for a total transaction of $67,197.24. Following the transaction, the insider directly owned 168,235 shares of the company’s stock, valued at $7,883,492.10. This trade represents a 0.85% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Walid Abi-Saab also recently made the following trade(s):

• On Friday, May 8th, Walid Abi-Saab sold 45,000 shares of uniQure stock. The stock was sold at an average price of $25.06, for a total value of $1,127,700.00.

uniQure Price Performance

Shares of uniQure stock opened at $46.06 on Wednesday. The business’s fifty day moving average price is $29.02 and its 200 day moving average price is $23.40. uniQure N.V. has a twelve month low of $8.73 and a twelve month high of $71.50. The company has a current ratio of 10.40, a quick ratio of 10.40 and a debt-to-equity ratio of 0.33. The stock has a market capitalization of $2.91 billion, a P/E ratio of -13.24 and a beta of 0.98.

uniQure (NASDAQ:QURE) last announced its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) EPS for the quarter, topping the consensus estimate of ($0.88) by $0.03. The company had revenue of $3.56 million during the quarter, compared to analyst estimates of $5.21 million. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%. As a group, research analysts anticipate that uniQure N.V. will post -3.65 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have weighed in on QURE shares. Stifel Nicolaus set a $28.00 price target on shares of uniQure in a research report on Tuesday, May 5th. Royal Bank Of Canada increased their price objective on shares of uniQure from $35.00 to $65.00 and gave the stock an “outperform” rating in a research report on Thursday, June 18th. Sanford C. Bernstein downgraded shares of uniQure to a “market perform” rating in a research note on Tuesday, March 3rd. TD Cowen restated a “buy” rating on shares of uniQure in a report on Tuesday, March 3rd. Finally, Wall Street Zen raised shares of uniQure from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. Twelve equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $64.17.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Woodline Partners LP lifted its holdings in uniQure by 25.0% in the 1st quarter. Woodline Partners LP now owns 175,806 shares of the biotechnology company’s stock worth $1,864,000 after buying an additional 35,175 shares in the last quarter. Legal & General Group Plc acquired a new position in shares of uniQure in the second quarter worth about $497,000. Marshall Wace LLP lifted its stake in shares of uniQure by 276.5% in the second quarter. Marshall Wace LLP now owns 222,979 shares of the biotechnology company’s stock worth $3,108,000 after acquiring an additional 163,749 shares in the last quarter. California State Teachers Retirement System acquired a new position in shares of uniQure in the second quarter worth about $540,000. Finally, Ameriprise Financial Inc. boosted its holdings in uniQure by 38.6% in the second quarter. Ameriprise Financial Inc. now owns 761,948 shares of the biotechnology company’s stock valued at $10,622,000 after purchasing an additional 212,218 shares during the last quarter. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.